Budesonide/Glycopyrronium/Formoterol: a New Combination Inhaler for the Treatment of Chronic Obstructive Pulmonary Disease

Abstract

Chronic obstructive pulmonary disease (COPD) significantly impacts patients' quality of life and can lead to death, particularly in moderate to severe COPD patients with blood eosinophil levels of 300 cells/microlitre or higher. A new gas-based inhaled combination medication, Breztri Aerosphere^®, has been developed. It contains budesonide, glycopyrronium, and formoterol, utilizing "Aerosphere^®" technology. This technology ensures consistent medication particle suspension after shaking, allowing for effective delivery to the lungs. The medication is indicated for adult patients with moderate to severe COPD who are inadequately controlled with LABA/ICS or LABA/LAMA therapies. Studies have shown that Breztri Aerosphere^® improved lung function, reduced the risk of moderate to severe COPD exacerbations by 52%, and decreased hospitalization or mortality rates by 46%. Common side effects include nasopharyngitis and upper respiratory tract infections. Pharmacoeconomic analysis suggests that Breztri Aerosphere^® is a cost-effective treatment option for moderate to severe COPD compared to LABA/ICS or LABA/LAMA. Therefore, Breztri Aerosphere^® is a viable treatment choice for moderate to severe COPD, especially for elderly patients with inhaler usage difficulties, due to its ease of use.